Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2025-12-26 @ 2:59 AM
Study NCT ID:
NCT01798602
Status:
TERMINATED
Last Update Posted:
2013-02-26
First Post:
2013-02-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial
Sponsor:
Canadian Critical Care Trials Group
Organization:
Study Overview
Official Title:
Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial
Status:
TERMINATED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
H1N1 pandemic concluded
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHAT Pilot
Brief Summary:
The CHAT Pilot Trial is designed to compare rosuvastatin against placebo in patients with suspected H1N1. The pilot study will assess the feasibility of our clinical protocols, and study procedures.
Detailed Description:
This trial is a pilot study to assess the feasibility and acceptability of a double blind randomized controlled trial (RCT) evaluating the efficacy of rosuvastatin as adjuvant therapy for H1N1 influenza
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: